Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$12.48 USD
+0.15 (1.22%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $12.47 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Cartesian Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
RNAC 12.48 +0.15(1.22%)
Will RNAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNAC
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?
Other News for RNAC
Cartesian: Autoimmune Cell Therapy Excites, But Reality Bites
RNAC: Wedbush Foresees Promising Future for Cartesian Therapeutics | RNAC Stock News
Wedbush bullish on Cartesian Therapeutics, initiates with an Outperform
Wedbush Initiates Coverage on RNAC with Outperform Rating | RNAC Stock News
Wedbush Sees Upside Potential for Cartesian Therapeutics (RNAC) with Outperform Rating | RNAC ...